We are live on
!
Find out more
VU
Valence8 US Portfolio holdings
AUM
$286M
1-Year Est. Return
22.37%
This Fund
S&P 500
This Quarter
Est. Return
-2.5%
1 Year Est. Return
+22.37%
3 Year Est. Return
+53.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$208M
AUM Growth
-$32.9M
(-14%)
Cap. Flow
-$25.7M
Cap. Flow
% of AUM
-12.33%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
63
New
1
Increased
4
Reduced
5
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Expanded Tech-Software Sector ETF
IGV
|
+$7.72M |
| 2 |
iShares MSCI EAFE Value ETF
EFV
|
+$277K |
| 3 |
Vanguard Value ETF
VTV
|
+$135K |
| 4 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$72.6K |
| 5 |
State Street Utilities Select Sector SPDR ETF
XLU
|
+$24.4K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Japan ETF
EWJ
|
+$3.45M |
| 2 |
iShares MSCI United Kingdom ETF
EWU
|
+$3.3M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$2.2M |
| 4 |
iShares MSCI USA Quality Factor ETF
QUAL
|
+$1.92M |
| 5 |
iShares MSCI Intl Quality Factor ETF
IQLT
|
+$1.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 0% |
| 2 | Healthcare | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Ultragenyx Pharmaceutical
RARE
$2.88B
| – | – |
-4,241
| Closed | -$236K |
|
52
Relay Therapeutics
RLAY
$4.34B
| – | – |
-26,200
| Closed | -$185K |
|
|
FLNA
53
PUT
Filana Therapeutics
FLNA
$51.2M
| – | – |
-14,100
| Closed | -$415K |
|
54
Solid Biosciences
SLDB
$858M
| – | – |
-15,728
| Closed | -$110K |
|
|
SLNO
55
CALL
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-12,500
| Closed | -$631K |
|
|
SLNO
56
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-9,706
| Closed | -$490K |
|
57
Tyra Biosciences
TYRA
$1.91B
| – | – |
-13,188
| Closed | -$310K |
|
58
Vir Biotechnology
VIR
$1.59B
| – | – |
-33,650
| Closed | -$252K |
|
59
CALL
Viridian Therapeutics
VRDN
$1.99B
| – | – |
-13,100
| Closed | -$298K |
|
60
VistaGen Therapeutics
VTGN
$9.4M
| – | – |
-34,376
| Closed | -$103K |
|
61
Zura Bio
ZURA
$518M
| – | – |
-17,495
| Closed | -$71K |
|
62
Zevra Therapeutics
ZVRA
$755M
| – | – |
-21,596
| Closed | -$150K |
|
|
CLYM
63
Climb Bio
CLYM
$727M
| – | – |
-12,045
| Closed | -$61.3K |
|
Similar funds
A
MC
IRAG
4WM
MAG
HMP
SIIL
LCM
Valence8 US's Q4 2024 Portfolio in Review
As of Q4 2024, Valence8 US held 63 positions worth $208M, down 14% from $241M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Valence8 US withdrew a net $25.7M in Q4 2024, closing 53 positions and reducing 5 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $999K position sold in full.
By sector, the portfolio is most concentrated in Financials at 0% of assets, down from 0.02% a quarter earlier, followed by Healthcare.
Against the trend, Valence8 US opened a new position in iShares Expanded Tech-Software Sector ETF worth $7.8M.
- Valence8 US's largest Q4 2024 buy was iShares Expanded Tech-Software Sector ETF: 77,909 shares worth $7.8M.
- Valence8 US added most to iShares MSCI EAFE Value ETF in Q4 2024, an estimated $277K increase.
- Valence8 US's biggest Q4 2024 reduction was iShares MSCI Japan ETF, cutting an estimated $3.45M.
- Valence8 US fully exited Jazz Pharmaceuticals in Q4 2024, selling an estimated $999K.
- Valence8 US's ten largest holdings make up 100% of its $208M portfolio in Q4 2024.
- Valence8 US opened 1 new position and closed 53 in Q4 2024.
- Valence8 US's portfolio value fell 14% quarter-over-quarter to $208M.
Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.